PharmaEngine, Inc. is a biopharmaceutical company established in February 2003 with funding from TTY Biopharm and Taiwanese venture capitalcompanies. PharmaEngine is a networked pharma company that operates according to a “No Research, Development Only (NRDO)” model. It is led by Dr. Grace Yeh and supported by a strong network of reputable advisors and consultants worldwide.
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 3 projects in the pipeline. ONIVYDE®(PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug(irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, was approved by both the US FDA and Taiwan FDA in 2015, European Medicines Agency (EMA) in 2016, Korea MFDS and SingaporeHAS in 2017. PEP503 (NBTXR3), a nanoparticle working as a radio-enhancer,is in a positive global pivotal trial of soft tissue sarcoma, theother ongoing studies arein Phase I/II trial inhead and neck cancerand rectal cancer in Taiwan. PEP06, a new chemical entity (NCE) for cancer treatment, is currently in the pre-clinical stage.
In April 2017, Ipsen S.A., a French company, completed the acquisition of ONIVYDE®from Merrimack Pharmaceuticals, Inc. for the US marketing and sales and became the new corporate partner of PharmaEngine, Inc. PharmaEngine and Ipsen are now working closely to complete NDA for worldwide approval of ONIVYDE®in the post-gemcitabine metastatic pancreatic cancer and also life cycle management of ONIVYDE®of new indications.
Meanwhile, PharmaEngine continuously puts the best efforts tomove forward the clinical and pre-clinical developments of PEP503 (NBTXR3) and PEP06. Furthermore, PharmaEngine is actively seeking to in-license new projects for preclinical/clinical development and commercialization.
PharmaEngine has adapted the “no research, development only model (NRDO)” as well as “networked pharma model” for new drug development. We license in drug candidates for drug development, taking them through various stages ranging from preclinical to clinical and further out-licensing.
We are an integrated development company with strong expertise in identifying and executing strategies for drug development that can leverage development resources through collaborative arrangements with partners in our global network.